×
Pfizer Cash on Hand 2010-2025 | PFE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pfizer cash on hand for the quarter ending March 31, 2025 was
$17.317B
, a
45.18% increase
year-over-year.
Pfizer cash on hand for 2024 was
$20.477B
, a
61.36% increase
from 2023.
Pfizer cash on hand for 2023 was
$12.69B
, a
44.18% decline
from 2022.
Pfizer cash on hand for 2022 was
$22.732B
, a
26.83% decline
from 2021.
View More
Pfizer Cash on Hand 2010-2025 | PFE
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Pfizer cash on hand for 2024 was
$20.477B
, a
61.36% increase
from 2023.
Pfizer cash on hand for 2023 was
$12.69B
, a
44.18% decline
from 2022.
Pfizer cash on hand for 2022 was
$22.732B
, a
26.83% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Eli Lilly (LLY)
$796.4B
Johnson & Johnson (JNJ)
$379.5B
AbbVie (ABBV)
$306B
Novo Nordisk (NVO)
$260.6B
Roche Holding AG (RHHBY)
$248.1B
Novartis AG (NVS)
$234.2B
Merck (MRK)
$196.7B
Sanofi (SNY)
$128.6B
Bayer (BAYRY)
$23.7B
Innoviva (INVA)
$1.1B